Join TScan Therapeutics for a virtual KOL event, featuring Monzr M. Al Malki, MD (City of Hope) who will review the initial results from the Phase 1 trial of TSC-100 and TSC-101 presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, and discuss the potential for T cell receptor (TCR)-engineered T cell therapies (TCR-T) in cancer.

TSC-100 and TSC-101, TScan’s lead TCR-T candidates, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation with reduced intensity conditioning.

A live question and answer session will follow the prepared remarks.